BioMS completes MS Phase II

BioMS Medical (Edmonton, Alberta) completed a 42-month Phase II study of its MBP8298 synthetic myelin basic protein (MBP) peptide in 32 patients with chronic progressive multiple sclorosis (MS). The p...